InvestorsHub Logo
Followers 13
Posts 3218
Boards Moderated 0
Alias Born 04/26/2007

Re: None

Wednesday, 05/05/2021 7:15:48 PM

Wednesday, May 05, 2021 7:15:48 PM

Post# of 40491
It’s looking like NVAX wasn’t that efficacious. If you’re HIV positive, you’re basically screwed at 49%. If you’re negative HIV, then you are at 60%.

RESULTS
Of 6324 participants who underwent screening, 4387 received at least one injection of vaccine or placebo. Approximately 30% of the participants were seropositive for SARS-CoV-2 at baseline. Among 2684 baseline seronegative participants (94% HIV-negative and 6% HIV-positive), predominantly mild-to-moderate Covid-19 developed in 15 participants in the vaccine group and in 29 in the placebo group (vaccine efficacy, 49.4%; 95% confidence interval [CI], 6.1 to 72.8). Vaccine efficacy among HIV-negative participants was 60.1% (95% CI, 19.9 to 80.1). Of 41 sequenced isolates, 38 (92.7%) were the B.1.351 variant. Post hoc vaccine efficacy against B.1.351 was 51.0% (95% CI, -0.6 to 76.2) among the HIV-negative participants. Preliminary local and systemic reactogenicity events were more common in the vaccine group; serious adverse events were rare in both groups.

https://www.nejm.org/doi/full/10.1056/NEJMoa2103055?query=featured_coronavirus
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News